DHR vs RTX: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and RTX Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Danaher Corporation · Healthcare
$177.17
+8.9% upside to fair value
Grade B
High Quality
VS
RTX Corporation · Industrials
$185.60
-25.2% upside to fair value
Grade D
QuantHub Verdict
DHR has more upside to fair value
(+8.9%).
DHR trades at a lower forward P/E
(34.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
RTX |
| Current Price |
$177.17 |
$185.60 |
| Fair Value Estimate |
$192.90 |
$138.81 |
| Upside to Fair Value |
+8.9%
|
-25.2%
|
| Market Cap |
$125.4B |
$249.9B |
| Forward P/E |
34.1x
|
34.3x
|
| EV / EBITDA |
20.8x
|
18.3x
|
| Price / Sales |
5.1x
|
2.8x
|
| Price / FCF |
23.7x
|
29.9x
|
| Revenue Growth YoY |
+3.7%
|
+8.7%
|
| Gross Margin |
60.7%
|
20.2%
|
| Operating Margin |
21.0%
|
10.9%
|
| Return on Equity |
7.1%
|
11.2%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.22%
|
3.34%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specializing in medical diagnostics and research tools through three balanced platforms: Biotechnology, Life Sciences, and Diagnostics. The company benefits from a durable competitive moat supported by the Danaher Business System, disciplined capital allocation, and a platform-centric organizational structure. Despite modest revenue growth of…
RTX Corporation is a leading aerospace and defense company with a strong competitive moat driven by scale and an installed base in commercial aerospace via Pratt & Whitney and Collins Aerospace, and defense through Raytheon. The company benefits from a large multi-year backlog of approximately $270 billion supporting steady cash flow and mid-single-digit organic growth. Despite solid revenue grow…
Accumulation Zones
| Metric |
DHR |
RTX |
| Zone Low |
$144.68 |
$104.11 |
| Zone High |
$163.97 |
$117.99 |
| In Buy Zone? |
No
|
No
|